$29.17
Value $1.2B
AMPH and JNJ stock compared: price, dividend, valuation and results, from SEC filings.
$29.17
Value $1.2B
$282.55
Value $681B
Amphastar Pharmaceuticals (AMPH) has a market value of $1.2B and Johnson & Johnson (JNJ) $681B. Over the last year, with dividends, AMPH moved +11.9% and JNJ +47.5%. The P/E is 12.6 for AMPH and 42.3 for JNJ. Dividend yield: AMPH none, JNJ 1.87%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
AMPH$1.2B
JNJ$681B
JNJ is 547 times AMPH
Revenue, 12 months
AMPH$746M
JNJ$99.3B
JNJ is 133 times AMPH
Net income, 12 months
AMPH$99M
JNJ$16.1B
JNJ is 163 times AMPH
Operating margin
AMPH18.7%
JNJ–
ROIC
AMPH7.6%
JNJ12.4%
4.7 points apart
P/E
AMPH12.6
JNJ42.3
JNJ is 3.4 times AMPH
Dividend yield
AMPH0.0%
JNJ1.9%
1.9 points apart
5-year return
AMPH+37.9%
JNJ+98.6%
60.7 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
AMPH+37.9%
JNJ+98.6%
| Period | AMPHWith dividends | JNJWith dividends |
|---|---|---|
| 1 year since November 14, 2025 | +11.9%Price +11.9% | +47.5%Price +44.2% |
| 3 years since November 16, 2023 | -48.1%-19.6% a yearPrice -48.1% | +105.0%+27.0% a yearPrice +88.2% |
| 5 years since November 15, 2021 | +37.9%+6.6% a yearPrice +37.9% | +98.6%+14.7% a yearPrice +72.8% |
| 10 years since November 16, 2016 | +37.4%+3.2% a yearPrice +37.4% | +218.6%+12.3% a yearPrice +142.8% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
AMPHAmphastar PharmaceuticalsJNJJohnson & Johnson
| Price | $29.17 | $282.55 |
|---|---|---|
| Market value | $1.2B | $681B |
| Enterprise value (EV) | $1.6B | $708B |
| P/E | 12.6 | 42.3 |
| P/E, 5-year median | 16.1 | 21.9 |
| P/B | 1.5 | 8.4 |
| EV/EBIT | 11.6 | 39.9 |
| Free cash flow yield | 11.2% | 3.0% |
| Revenue, 12 months | $746M | $99.3B |
|---|---|---|
| Net income, 12 months | $99M | $16.1B |
| Free cash flow, 12 months | $139M | $20.6B |
| Earnings per share, 12 months | $2.19 | $6.59 |
| Revenue growth, year on year | -1.7% | 6.1% |
| Revenue growth a year, past | +15.5%over 5 years | +2.7%over 5 years |
| EPS growth a year, past | +132.3%over 5 years | +14.9%over 5 years |
| Gross margin | 46.8% | 67.6% |
|---|---|---|
| Operating margin | 18.7% | – |
| Net margin | 13.3% | 16.2% |
| ROIC | 7.6% | 12.4% |
| ROE | 12.6% | 19.7% |
| Cash | $231M | $17.2B |
|---|---|---|
| Total debt | $692M | $44.7B |
| Net debt / EBITDA | 2.2 | 1.1 |
| Interest cover | 5.3× | 18.0× |
| Dividend yield | – | 1.9% |
|---|---|---|
| Dividend per share, 12 months | – | $5.28 |
| Dividend growth a year, past | – | +5.3%over 5 years |
| Buyback yield | 6.1% | 0.9% |
| Shareholder yield | 6.1% | 2.7% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Johnson & Johnson ($681B) is about 547.3 times Amphastar Pharmaceuticals ($1.2B), at today's prices.
Since November 16, 2016, AMPH's price moved +37.4% and JNJ's +142.8%. With dividends: AMPH +37.4% (+3.2% a year), JNJ +218.6% (+12.3% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for Amphastar Pharmaceuticals and 1.87% for Johnson & Johnson. Over the last twelve months they paid – and $5.28 per share.
At today's price, the P/E is 12.6 for AMPH and 42.3 for JNJ. The median of the last five years was 16.1 and 21.9, which shows where each stands against its own past.
Over the last twelve months, the net margin was 13.3% for Amphastar Pharmaceuticals and 16.2% for Johnson & Johnson, and the operating margin 18.7% and –. Revenue was $746M and $99.3B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.